1. Passaretti S, Franzoni M, Comin U, et al. Action of glucomannans on complaints in patients affected with chronic constipation: a multicentric clinical evaluation. Ital J Gastroenterol 1991;23:421–5.
2. Marzio L, Del Bianco R, Donne M, et al. Mouth-to-cecum transit time in patients affected by chronic constipation: effect of glucomannan. Am J Gastroenterol 1989;84:888–91.
3. Marsicano LJ, Berrizbeitia ML, Mondelo A. Use of glucomannan dietary fiber in changes in intestinal habit. G E N 1995;49:7–14 [in Spanish].
4. Signorelli P, Croce P, Dede A. A clinical study of the use of a combination of glucomannan with lactulose in the constipation of pregnancy. Minerva Ginecol 1996;48:577–82 [in Italian].
5. Staianno A, Simeone D, Giudice ED, et al. Effect of the dietary fiber glucomannan on chronic constipation in neurologically impaired children. J Pediatr 2000;136:41–5.
6. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care 1999;22:913–9.
7. Zhang MY, Huang CY, Wang X, et al. The effect of foods containing refined Konjac meal on human lipid metabolism. Biomed Environ Sci 1990;3:99–105.
8. Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Am J Clin Nutr 1995;61:585–9.
9. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1984;8:289–93.
10. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care 2000;23:9–14.
11. Landin K, Holm G, Tengborn L, Smith U. Guar gum improves insulin sensitivity, blood lipids, blood pressure, and fibrinolysis in healthy men. Am J Clin Nutr 1992;56:1061–5.
12. Cavallo-Perin P, Bruno A, Nuccio P, et al. Dietary guar gum supplementation does not modify insulin resistance in gross obesity. Acta Diabetol Lat 1985;22:139–142.
13. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr 1995;49(Suppl. 3):S190–7 [review].
14. Melga P, Giusto M, Ciuchi E, et al. Dietary fiber in the dietetic therapy of diabetes mellitus. Experimental data with purified glucomannans. Riv Eur Sci Med Farmacol 1992;14:367–73 [in Italian].
15. Huang CY, Zhang MY, Peng SS, et al. Effect of Konjac food on blood glucose level in patients with diabetes. Biomed Environ Sci 1990;3:123–31.
16. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care 1999;22:913–9.
17. Vorster HH, Lotter AP, Odendaal I, et al. Benefits from supplementation of the current recommended diabetic diet with gel fibre. Int Clin Nutr Rev 1988;8:140–6.
18. Cesa F, Mariani S, Fava A, et al. The use of vegetable fibers in the treatment of pregnancy diabetes and/or excessive weight gain during pregnancy. Minerva Ginecol 1990;42:271–4 [in Italian].
19. Kimm SY. The role of dietary fiber in
the development and treatment of childhood obesity. Pediatrics 1995;96:1010–4.
20. Livieri C, Novazi F, Lorini R. The use of highly
purified glucomannan-based fibers in childhood obesity. Pediatr Med Chir
1992;14:195–8 [in Italian].
21. Vido L, Facchin P,
Antonello I, et al. Childhood obesity treatment: double blinded trial on
dietary fibres (glucomannan) versus placebo. Padiatr Padol 1993;28:133–6.
22. Biancardi G, Palmiero L, Ghirardi PE. Glucomannan in the treatment of overweight patients with osteoarthritis. Curr Ther Res 1989;46:908–12.
23. Vita PM, Restelli A, Caspani P, Klinger R. Chronic use of glucomannan in the dietary treatment of severe obesity. Minerva Med 1992;83:135–9 [in Italian].
24. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1984;8:289–93.
25. Livieri C, Novazi F, Lorini R. The use of highly purified glucomannan-based fibers in childhood obesity. Pediatr Med Chir 1992;14:195–8 [in Italian].
26. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995;9:33–9.
27. Hopman WP, Houben PG, Speth PA, Lamers CB. Glucomannan prevents postprandial hypoglycaemia in patients with previous gastric surgery. Gut 1988;29:930–4.
28. Kneepkens CM, Fernandes J, Vonk RJ. Dumping syndrome in children. Diagnosis and effect of glucomannan on glucose tolerance and absorption. Acta Paediatr Scand 1988;77:279–86.
29. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr 1995;49(3 Suppl):190S–197S [review].
30. Marsicano LJ, Berrizbeitia ML, Mondelo A. Use of glucomannan dietary fiber in changes in intestinal habit. G E N 1995;49:7–14 [in Spanish].
31. Passaretti S, Franzoni M, Comin U. et al. Action of glucomannans on complaints in patients affected with chronic constipation: a multicentric clinical evaluation. Ital J Gastroenterol 1991;23:421–5.
32. Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Am J Clin Nutr 1995;61:585–9.
33. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care 1999;22:913–9.
34. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care 2000;23:9–14.
35. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care 1999;22:913–9.
36. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care 2000;23:9–14.
37. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1984;8:289–93.
38. Vita PM, Restelli A, Caspani P, Klinger R. Chronic use of glucomannan in the dietary treatment of severe obesity. Minerva Med 1992;83:135–9 [in Italian].
39. Henry DA, Mitchell AS, Aylward J, et al. Glucomannan and risk of oesophageal obstruction. Br Med J 1986;292:591–2.
40. Werley MS, Burleigh-Flayer H, Mount EA, Kotkoskie LA. Respiratory sensitization to konjac flour in guinea pigs. Toxicology 1997;124:115–24.